UBE2K was identified as a target of the central nervous system stimulant, dextroamphetamine, used to treat attention-deficit disorder (ADHD) and narcolepsy, however its use has been federally controlled due to the high potential for abuse. Here, UBE2K is linked to attention deficit-hyperactivity disorder.